WACKER and Biosyntia Develop Large-Scale Production Process for Sustainable Biotin
Munich / Copenhagen, 11. January 2022 – Danish biotech company Biosyntia and the Munich-based WACKER Group today announced the signing of a contract to develop a large-scale production process for fermentation-based biotin. The long-term partnership aims to make fermentation-based biotin available for the full range of relevant applications as a sustainable, non-chemical, European-sourced alternative.För mer information se bifogad pressrelease.